The administration of ION363 in a juvenile-onset FUS ALS patient carrying the FUSP525L mutation via repeated intrathecal infusions with increased monthly doses from 20 mg to 120 mg over 10 months led to a substantial reduction in wild-type and mutant FUS expression throughout the central nervous system. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.